Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina; Manuela Ludovisi; Giacomo Corrado; Vito Carone; Vanda Salutari; Marco Petrillo; Giovanni Scambia

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina, Manuela Ludovisi, Giacomo Corrado, Vito Carone, Vanda Salutari, Marco Petrillo, Giovanni Scambia

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

18 Citazioni (Scopus)

Lingua originale	English
pagine (da-a)	187-193
Numero di pagine	7
Rivista	Gynecologic Oncology
Stato di pubblicazione	Pubblicato - 2008

Keywords

CA125
Ovarian cancer
prognostic role
response to chemotherapy

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{1970295c85204ce0a3622019b20a57ac,

title = "Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.",

keywords = "CA125, Ovarian cancer, prognostic role, response to chemotherapy, CA125, Ovarian cancer, prognostic role, response to chemotherapy",

author = "Ferrandina, {Maria Gabriella} and Manuela Ludovisi and Giacomo Corrado and Vito Carone and Vanda Salutari and Marco Petrillo and Giovanni Scambia",

year = "2008",

language = "English",

pages = "187--193",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Orlando, Fla. : Academic Press",

}

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. / Ferrandina, Maria Gabriella; Ludovisi, Manuela; Corrado, Giacomo et al.
In: Gynecologic Oncology, 2008, pag. 187-193.

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

AU - Ferrandina, Maria Gabriella

AU - Ludovisi, Manuela

AU - Corrado, Giacomo

AU - Carone, Vito

AU - Salutari, Vanda

AU - Petrillo, Marco

AU - Scambia, Giovanni

PY - 2008

Y1 - 2008

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

UR - http://hdl.handle.net/10807/31923

M3 - Article

SN - 0090-8258

SP - 187

EP - 193

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -